Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Fig. 3

Treatment outcome in (a) Panels 1–3, and (b) Panel 4. SVR12 data shown represent SVR12 achieved after treatment with only the combination of SMV + TMC647055/RTV ± RBV. In the Panel 2 GT1b/with RBV and GT1b/without RBV arms, four and two patients, respectively, had follow-up therapy with pegIFN/RBV and are, therefore, not included in the SVR12 category that focuses on SVR12 after 12 weeks of DAA treatment. Among them, five patients achieved SVR12 after completing follow-up therapy; one patient refused to receive follow-up treatment and was lost to follow-up. One additional patient in the Panel 2 GT1b/without RBV group had <25 IU/mL detectable HCV RNA at Week 4 and, therefore, met the criterion for the 12-week follow-up treatment with pegIFN/RBV; however, this patient refused to receive follow-up treatment. DAA direct-acting antiviral agent, DET detectable, EOT end of treatment, FU follow-up, GT genotype, HCV hepatitis C virus, pegIFN pegylated interferon α-2a, RBV ribavirin, RTV ritonavir, SMV simeprevir, SVR12 sustained virologic response 12 weeks after end of treatment, VBT viral breakthrough

Back to article page